[1] |
CHEN Qun, ZHU Heping, YUAN Xiaolong.
Analysis of 197 cases of pentoxifylline injection and exploring supervision mode of rational drug use in hospitals
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 948-953.
|
[2] |
LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HE Qing, HUANG Kai.
Analysis of reasons for screening failure of healthy subjects in clinical trials of orally inhaled drug products
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 758-766.
|
[3] |
WANG Lin, YU Jianguo, LI Xiao, LUAN Jiajie.
Establish and implement a pre-prescription system for outpatient based on Six Sigma DMAIC model
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 780-787.
|
[4] |
MA Guangli, ZHANG Jing.
Application of quantitative pharmacology in vaccine research and de-velopment: overview and prospect
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 315-322.
|
[5] |
LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HUANG Kai.
Safety analysis on bioequivalence studies of orally inhaled drug products in healthy Chinese subjects#br#
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1131-1138.
|
[6] |
YE Hongbo, SONG Yangyang, XUE Ling, RUI Jianzhong.
Meropenem population pharmacokinetic model for the Chinese elderly established by model-based META analysis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 984-990.
|
[7] |
CHEN Jian, LAN Yu, WU Yong, SHEN Boxiong.
Effects of intestinal flora disturbance on postoperative cognitive dysfunction in patients with inhalation anesthesia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 639-644.
|
[8] |
SONG Yan, GAO Linyan, ZHANG Yanping, LI Xiang, ZHANG Lan.
Application of medical failure mode and effect analysis in blood sample management in phase I clinical trials#br#
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1031-1036.
|
[9] |
JIAO Zhigang, FAN Ru, XU Biyun, CHEN Sizhen, ZANG Yiteng, WANG shiyuan, CHEN Bingwei .
Multiple imputation of missing data in clinical longitudinal studies and its sensitivity analyses
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1037-1041.
|
[10] |
CHE Jinjing, LI Na.
General considerations on bioanalytical methods for comparative evaluation of biosimilars immunogenicity
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 721-728.
|
[11] |
XU Runze, HAN Jingjing, LI Wenqian, YANG Jin.
Advances in risk assessment systems from non-clinical to clinical arrhythmia stages
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 423-433.
|
[12] |
ZHU Xueya, LI Zeyun, TIAN Xin, ZHANG Xiaojian.
Research progress of monoclonal antibodies in pharmacokinetic characteristics, analysis methods and method validation
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 113-120.
|
[13] |
YU Zhaolei, BAI Jianling, YU Hao, ZHAO Yang.
Development of tools for clinical trial information retrieval and Meta-analysis based on R-Shiny: Taking non-small cell lung cancer as an example
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 984-991.
|
[14] |
ZHU Tianyi, CAI Jingjing, HUANG Jiajun, GENG Zheng, ZHAO Yang, LOU Donghua, YU Hao, BAI Jianling.
Application of ADaM in safety analysis of bioequivalence trail of generic drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 658-663.
|
[15] |
LI Jian, YANG Jinbo, WANG Yuzhu.
Discussion on the format and content of new drug population pharmacokinetic study report
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 546-549.
|